To decrease the immunogenicity ?f anti-MHC class II (coded by the (MoAb 29Al, Dept. of Immunel. rat kidneys, grafts were perfused with an l-E subregi on) mouse monoe 1 ona 1 ant i body Kiel) as described previously (5). How effectively class lI-positive cells, which were mainly dendritic in appearance, were surface labelled by this procedure was checked by staining MoAb-perfused k i dney sect ions with peroxi dase-conjugated rabbi t ant i ··mouse antiglobulin and comparing them with in vitra MoAb-incubated sections. The results are presented in Table I .
.
Furthermore, it was shown that during the first day after transplantation donor cells migrated into the recipient's spleen and mesenteric 1ymph nades. The number of these cells located within the spleen's lymphoid follicles was smaller when the transplanted organ was perfused with MoAb RAT KIDNEY GRAFT SURVIVAL 
1I
Dur findings suggest that a bidirectional sys,tem of cell migration between the graft and the host ex-j sts whi ch may provi de both "centra 1 " and peripheral" al10antigen presentation. In "central" sensitization donor ce 11 s part i ci pate by mi grat ion i nto the reci p'j ent I s spleen. The phenomenon of dendritic cell migration was recent1y reviewed by Austyn and Larsen (2).
In "peripheral" sensitization host cells participate by penetration into the graft, and donor cel1s by 10cal antigen presentation. The role of host ce 11 s in a 11 oanti gen presentat i on has been studi ed and confi rmed by Ishikura at a1. (3), and Sherwood et a1. (7) . Ruers at al. (6) concluded from their studü~s that the local events of allograft sensitization playa crucial role in the rejection response.
Taking into consideration that graft rejection may be induced in these two ways we found it reasonable to combine MoAb perfusion of rat kidney with a low dose of the new i mmunosuppres si ve agent 1 !:;-deoxyspergua 1 in (15-00S) (1) which ;s known to interfere with antigen presentation. To determine the minimum effective dose of 15-00S, doses of 0.05, 0.2, 0.3 and 0.5 mg/kg were gi ven i ntraperi tonea 11y for 14 days to LEW rats recel Vl ng DA ki dney grafts. Graft survi val in rats treated with vari ous doses of 15-00S i s presented in Tab1e Ir1.
On the basis of these resu1ts a dose of 0.2 mg/kg was se1ected for further studi es. I n LEW rats recei vi ng MoAb-perfused ki dney grafts, mean graft surviva1 was 146, :!:.16 days (n=3). These data suggest that the reduction of graft immunogenicity achieved by perfusion with MoAb became biologically relevant only in combination with a low dose of 15-00S. This low-dose, short-term treatment initiates long-standing surviva1 of an MHC fu11y a110geneic organ graft.
